FDA Approves Freenome SimpleScreen CRC Blood Test for Abbott
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
FDA Approves Freenome's SimpleScreen CRC Blood-Based Screening Test
Brisbane, Calif. and Abbott Park, Ill., USA - Freenome, Inc. (Nasdaq: FRNM) and Abbott (NYSE: ABT) have announced that the U.S. Food and Drug Administration (FDA) has granted approval for SimpleScreen CRC. This new blood-based screening test is designed for adults aged 45 and older who are at average risk for colorectal cancer (CRC). Abbott will exclusively commercialize the screening tool in the United States, offering a non-invasive option for the millions of Americans currently overdue for recommended screening.
Key Highlights
... Read on — Members only
About Freenome Holdings, Inc.
More FRNM News
Health
Strategic Partnership
Daily overview of upcoming SPAC and IPO events – from initial announcement to definitive agreement and public listing.
Discover last week’s SPAC and IPO highlights, key trends, and market updates. Stay informed with SpacStar.